Tactile Medical (NSDQ: TCMD) this week appointed Daniel Reuvers as president and CEO, effective June 8.
Reuvers succeeds Gerald Mattys who is retiring who will serve as a consultant for the company until June 2021.
“After a comprehensive search process which yielded several highly qualified candidates, I am very pleased to announce that the Board of Directors has voted unanimously to appoint Dan Reuvers to the role of President and Chief Executive Officer,” chairperson of the board Peter Soderberg said in a news release. “With more than 30 years of experience in the medical device industry, a proven track record of leading global medical device businesses and company leadership experience with our direct prescriber-to-payer-to-patient business model, we believe Dan is the ideal executive to lead Tactile Medical during its next stage of growth and value creation.”
Reuvers has more than 20 years of leadership experience in the life sciences industry. He most recently served as executive VP and president of Cowman Specialty Surgical at Integra Lifesciences. He also served as corporate VP and president of international at Integra and has held numerous leadership positions at Advanced Respiratory.
“I am honored and excited to join the team at Tactile Medical,” Reuvers said. “With its clinically proven, at-home treatment options, direct-to-patient and -provider business model and strong commercial, reimbursement and payer relations expertise, I believe Tactile Medical is uniquely positioned for continued strong growth in the market for chronic swelling conditions. I look forward to working together with our employees, executive management team and the Board of Directors, to increase the awareness and adoption of our at-home products in the $5+ billion U.S. lymphedema market for the benefit of both our customers and shareholders.”